Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer

[1]  W. Scheithauer,et al.  Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Daniel J Sargent,et al.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Muro,et al.  Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Jeffery,et al.  Follow-up strategies for patients treated for non-metastatic colorectal cancer. , 2016, The Cochrane database of systematic reviews.

[5]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[6]  F. Hughes,et al.  Quality of evidence , 2013, BDJ.

[7]  K. Kaneko,et al.  Long-term outcomes after resection for submucosal invasive colorectal cancers. , 2013, Gastroenterology.

[8]  Gordon H Guyatt,et al.  GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. , 2013, Journal of clinical epidemiology.

[9]  G. Guyatt,et al.  GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. , 2013, Journal of clinical epidemiology.

[10]  Elie A Akl,et al.  GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. , 2013, Journal of clinical epidemiology.

[11]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[12]  D. Goldstein,et al.  Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Conroy,et al.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Torsten Hothorn,et al.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. , 2012, The Lancet. Oncology.

[16]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[17]  G. Guyatt,et al.  GRADE guidelines 6. Rating the quality of evidence--imprecision. , 2011, Journal of clinical epidemiology.

[18]  Gordon H Guyatt,et al.  GRADE guidelines: 9. Rating up the quality of evidence. , 2011, Journal of clinical epidemiology.

[19]  Gordon H Guyatt,et al.  GRADE guidelines: 5. Rating the quality of evidence--publication bias. , 2011, Journal of clinical epidemiology.

[20]  G. Guyatt,et al.  GRADE guidelines: 8. Rating the quality of evidence--indirectness. , 2011, Journal of clinical epidemiology.

[21]  Gordon H Guyatt,et al.  GRADE guidelines: 7. Rating the quality of evidence--inconsistency. , 2011, Journal of clinical epidemiology.

[22]  Toshiaki Watanabe.  The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Colorectal cancers) , 2011 .

[23]  L. Mell,et al.  Population-based study of competing mortality in head and neck cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Ikematsu,et al.  Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: A retrospective multicenter study , 2011, Cancer science.

[25]  L. Boni,et al.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[27]  N. Petrelli,et al.  The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Kudo,et al.  MID‐TERM PROGNOSIS AFTER ENDOSCOPIC RESECTION FOR SUBMUCOSAL COLORECTAL CARCINOMA: SUMMARY OF A MULTICENTER QUESTIONNAIRE SURVEY CONDUCTED BY THE COLORECTAL ENDOSCOPIC RESECTION STANDARDIZATION IMPLEMENTATION WORKING GROUP IN JAPANESE SOCIETY FOR CANCER OF THE COLON AND RECTUM , 2011, Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society.

[29]  Howard Balshem,et al.  GRADE guidelines: 3. Rating the quality of evidence. , 2011, Journal of clinical epidemiology.

[30]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[31]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[32]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[33]  Josep Tabernero,et al.  Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[35]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Hartmann,et al.  Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). , 2010 .

[37]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Yuman Fong,et al.  American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[40]  C. Bokemeyer,et al.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[42]  R. Labianca,et al.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Y. Bang,et al.  Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Shinji Tanaka,et al.  Colorectal endoscopic submucosal dissection: present status and future perspective, including its differentiation from endoscopic mucosal resection , 2008, Journal of Gastroenterology.

[45]  G. Guyatt,et al.  Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive , 2008, BMJ : British Medical Journal.

[46]  Incorporating considerations of resources use into grading recommendations , 2008, BMJ : British Medical Journal.

[47]  Gordon H Guyatt,et al.  Incorporating considerations of resources use into grading recommendations , 2008, BMJ : British Medical Journal.

[48]  Gordon H Guyatt,et al.  GRADE: grading quality of evidence and strength of recommendations for diagnostic tests and strategies , 2008, BMJ : British Medical Journal.

[49]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[51]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[52]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[53]  W. Scheithauer,et al.  Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  H. Putter,et al.  The TME Trial After a Median Follow-up of 6 Years: Increased Local Control But No Survival Benefit in Irradiated Patients With Resectable Rectal Carcinoma , 2007, Annals of surgery.

[56]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Tjandra,et al.  Follow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis , 2007, Diseases of the colon and rectum.

[58]  L. Crinò,et al.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  P. Catalano,et al.  Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Adam.  Developing strategies for liver metastases from colorectal cancer. , 2007, Seminars in oncology.

[62]  J. Bosset,et al.  Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  K. Shirouzu,et al.  Indication and Benefit of Pelvic Sidewall Dissection for Rectal Cancer , 2006, Diseases of the colon and rectum.

[64]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  K. Bujko,et al.  Long‐term results of a randomized trial comparing preoperative short‐course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer , 2006, The British journal of surgery.

[66]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[67]  F. Luo,et al.  Hypoxia-inducible transcription factor-1α promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway , 2006, BMC Cancer.

[68]  P. Catalano,et al.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  C. V. D. van de Velde,et al.  Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  J. Berlin,et al.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  H. Putter,et al.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Egger,et al.  Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis , 2005, British Journal of Cancer.

[73]  Richard L Schilsky,et al.  Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.

[74]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[75]  I. Hyodo,et al.  Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Somerfield,et al.  American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Hidetaka Mochizuki,et al.  Risk factors for an adverse outcome in early invasive colorectal carcinoma. , 2004, Gastroenterology.

[78]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[79]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[80]  Toshihide Kumamoto,et al.  Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study , 2004, Journal of Gastroenterology.

[81]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  C. Earle,et al.  Follow-up of patients with curatively resected colorectal cancer: a practice guideline , 2003, BMC Cancer.

[83]  J. Berlin,et al.  Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  A. Oza,et al.  Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  J. Douillard,et al.  Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  J. Kievit.  Follow-up of patients with colorectal cancer: numbers needed to test and treat. , 2002, European journal of cancer.

[87]  M. Egger,et al.  Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials , 2002, BMJ : British Medical Journal.

[88]  P. Catalano,et al.  Surveillance for Second Primary Colorectal Cancer after Adjuvant Chemotherapy: An Analysis of Intergroup 0089 , 2002, Annals of Internal Medicine.

[89]  Rieken,et al.  [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer]. , 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[90]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  R. Peto,et al.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials , 2001, The Lancet.

[92]  J. Tjandra,et al.  Consensus statement of definitions for anorectal physiology and rectal cancer , 2001, Diseases of the colon and rectum.

[93]  J. Tjandra,et al.  Consensus statement of definitions for anorectal physiology and rectal cancer * , 2001, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[94]  E Harrison,et al.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  陆星华,et al.  Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis , 2001 .

[96]  L Pagliaro,et al.  Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. , 2000, JAMA.

[97]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  Takashi Shibata,et al.  Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma , 2000, Cancer.

[99]  K. Haruma,et al.  Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. , 2000, Oncology reports.

[100]  R. Barth,et al.  Interval hepatic resection of colorectal metastases improves patient selection. , 2000, Archives of surgery.

[101]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[102]  D. Weinberg,et al.  Surveillance after colorectal cancer resection , 2000, The Lancet.

[103]  T. Ishihara,et al.  Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[104]  P. Adeleine,et al.  Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Christian Jacques,et al.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer , 1998, The Lancet.

[106]  K. Sugihara,et al.  Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma , 1998, Cancer.

[107]  L. Spaggiari,et al.  Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. , 1998, The Annals of thoracic surgery.

[108]  M. Kerin.  Cancer principles and practice of oncology , 1997 .

[109]  L Påhlman,et al.  Improved survival with preoperative radiotherapy in resectable rectal cancer. , 1997, The New England journal of medicine.

[110]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[112]  R. Aitken,et al.  Mesorectal excision for rectal cancer , 1996, The British journal of surgery.

[113]  H. Thaler,et al.  Total mesorectal excision in the operative treatment of carcinoma of the rectum. , 1995, Journal of the American College of Surgeons.

[114]  A. Stiggelbout,et al.  Follow‐Up of Patients with Colorectal Cancer A Meta‐Analysis , 1994, Annals of surgery.

[115]  S. Kudo,et al.  Endoscopic Mucosal Resection of Flat and Depressed Types of Early Colorectal Cancer , 1993, Endoscopy.

[116]  H. Friza.  Report of a WHO Expert Committee. (WHO Technical Report Series No. 807), VI. World Health Organization, Geneva (1991), 65 pages, Soft cover SFr. 11 , 1993 .

[117]  W. Scheithauer,et al.  Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. , 1993, BMJ.

[118]  C. Akinsanya.  Cancer pain relief and palliative care , 1992 .

[119]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[120]  M. Ragozzino.  Detection and surveillance of colorectal cancer. , 1989, JAMA.

[121]  N. Petrelli,et al.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Jinnai Dennosuke,et al.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus , 1983 .

[123]  R. Heald,et al.  The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? , 1982, The British journal of surgery.

[124]  E. PeñaydelaPeña,et al.  [Cancer of the rectum]. , 1955, Revista de sanidad militar.

[125]  Gerald Gartlehner,et al.  [GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength]. , 2014, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[126]  Gerald Gartlehner,et al.  [GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence]. , 2013, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[127]  R. Greil,et al.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[128]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[129]  C. Camma',et al.  Preoperative Radiotherapy for Resectable Rectal Cancer , 2013 .

[130]  H. Schünemann,et al.  [GRADE guidelines: 9. Rating up the quality of evidence]. , 2013, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[131]  R. Greil,et al.  First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[132]  M. Hollands,et al.  A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases , 2012, Annals of Surgical Oncology.

[133]  大腸癌研究会.  Japanese classification of colorectal carcinoma , 2009 .

[134]  C. Fuchs,et al.  Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  P. Kim,et al.  Radiofrequency Ablation for Metachronous Liver Metastasis from Colorectal Cancer after Curative Surgery , 2007, Annals of Surgical Oncology.

[136]  Professor Jinnai Dennosuke President.  General rules for clinical and pathological studies on cancer of the colon, rectum and anus , 2006, The Japanese journal of surgery.

[137]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[138]  Nhs Trust.  Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and metaanalysis of randomised trials , 2003 .

[139]  L. Påhlman.  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Commentary , 2001 .

[140]  E. Blackstone,et al.  Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? , 1999, The Journal of thoracic and cardiovascular surgery.

[141]  Adjuvant therapy for patients with colon and rectum cancer. , 1990, Consensus statement. National Institutes of Health Consensus Development Conference.

[142]  E. Keeffe,et al.  Detection and surveillance of colorectal cancer. , 1989, JAMA.

[143]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[144]  C. Morgan.  Cancer of the rectum. , 1951, Annals of the Royal College of Surgeons of England.